Markets:

Overview

News

Currencies

International

Treasuries

Biodesix, Inc. - Common Stock (NQ:BDSX)

13.35 +0.60 (+4.71%)

Streaming Delayed Price Updated: 2:26 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biodesix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan

January 04, 2022

From Biodesix, Inc.

Via Business Wire

40 Biggest Movers From Friday ↗

January 03, 2022

Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean Intellectual Property Office has fully issued its...

Via Benzinga

4 Penny Stocks Insiders Are Buying ↗

December 23, 2021

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste...

Via Benzinga

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

Earnings Scheduled For August 10, 2021 ↗

August 10, 2021

Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:...

Via Benzinga

Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

December 08, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer

November 18, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix Partners with Spesana to Streamline Digital Access to Molecular Diagnostics for Precision Medicine in Lung Cancer

December 01, 2021

From Biodesix

Via Business Wire

Biodesix, Inc. (BDSX) Q3 2021 Earnings Call Transcript ↗

November 16, 2021

BDSX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Biodesix Announces Third Quarter 2021 Results and Highlights

November 15, 2021

From Biodesix, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021 ↗

November 17, 2021

Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:

Via Benzinga

Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting

November 12, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

November 11, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021

November 01, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting

October 13, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix's Return On Capital Employed Insights ↗

September 22, 2021

Biodesix (NASDAQ:BDSX) brought in sales totaling $11.88 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 89.63%, resulting in a loss of $...

Via Benzinga

Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer

September 16, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference

September 02, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists

August 25, 2021

From Biodesix, Inc.

Via Business Wire

4 Stocks Insiders Are Buying ↗

August 24, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...

Via Benzinga

66 Biggest Movers From Yesterday ↗

August 18, 2021

Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND...

Via Benzinga

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗

August 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (...

Via Benzinga

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

66 Biggest Movers From Yesterday ↗

August 12, 2021

Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last month, priced its IPO at $11 per share. Dyadic...

Via Benzinga

Topics Initial Public Offering

Why Did Biodesix Stock Fall 26% Today? ↗

August 11, 2021

Biodesix Inc's (NASDAQ: BDSX) second-quarter revenues grew 183% Y/Y to $11.9 million, but short of the $21.14 million consensus. COVID-19 testing revenues...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 11, 2021

Gainers Dyadic International (NASDAQ:DYAI) stock increased by 28.96% to $4.63 during Wednesday's regular session. Trading volume for this security as of 12:30 EST is...

Via Benzinga

Biodesix, Inc. (BDSX) Q2 2021 Earnings Call Transcript ↗

August 10, 2021

BDSX earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Biodesix Announces Second Quarter 2021 Results and Highlights

August 10, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference

August 02, 2021

From Biodesix, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biodesix, Inc. - Common Stock (NQ:BDSX)

All News about Biodesix, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today